Janine Boivin
Physician Assistant · Carmel, INNPI 1023024379
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Eli Lilly at 44.7% of the total. Among physician assistant clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $54.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$4K
- Lilly USA, LLC$1K
- Sumitomo Pharma America, Inc.$558
- Accord Healthcare, Inc.$317
- Pfizer$290
- Boston Scientific$287
- plus $2K from 34 others
What the payments were for
- Speaking & faculty fees$4,13844%
- Travel & lodging$1,01211%
- Food & beverage$3,99643%
- Education$2002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 8 | $4,173 |
| Lilly USA, LLC | 7 | $1,330 |
| Sumitomo Pharma America, Inc. | 21 | $558 |
| Accord Healthcare, Inc. | 13 | $317 |
| Pfizer | 14 | $290 |
| Boston Scientific | 6 | $287 |
| Astellas Pharma US Inc | 7 | $274 |
| Merck | 10 | $273 |
| AbbVie | 12 | $217 |
| Bayer | 7 | $177 |
| Medtronic | 8 | $153 |
| Tolmar, Inc. | 6 | $131 |
| Johnson & Johnson | 6 | $125 |
| Endo Pharmaceuticals Inc. | 5 | $109 |
| AstraZeneca | 4 | $95 |
| Endo USA, Inc. | 4 | $93 |
| Axonics, Inc. | 4 | $72 |
| Calyxo, Inc. | 3 | $64 |
| Dendreon Pharmaceuticals LLC | 2 | $54 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $49 |
| Myovant Sciences Inc. | 2 | $47 |
| Urogen Pharma, Inc. | 2 | $43 |
| Civco Medical Instruments | 1 | $41 |
| Myriad Genetic Laboratories, Inc. | 2 | $34 |
| Laborie Medical Technologies Corp. | 1 | $30 |
| Sanofi | 1 | $29 |
| Antares Pharma, Inc. | 2 | $28 |
| Novartis | 1 | $26 |
| Coloplast | 1 | $23 |
| Urovant Sciences Inc | 1 | $23 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Gilead | 1 | $20 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| Teleflex LLC | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Mission Pharmacal Company | 1 | $14 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KISUNLA$4,434
How this compares
$9,345 in reported general payments places this provider in the 95th percentile of 1,955 physician assistant providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 260 | $234,677 |
| MyrbetriqMirabegron | 189 | $196,058 |
| Mirabegron ErMirabegron | 24 | $23,869 |
| ElmironPentosan Polysulfate Sodium | 13 | $21,083 |
| Estradiol | 144 | $10,384 |
| PremarinEstrogens, Conjugated | 13 | $6,511 |
| Trimethoprim | 159 | $6,482 |
| Trospium Chloride | 34 | $3,565 |
| Desmopressin Acetate | 36 | $3,144 |
| Potassium Citrate ErPotassium Citrate | 14 | $2,117 |
| Tamsulosin Hcl | 147 | $2,034 |
| NitrofurantoinNitrofurantoin Macrocrystal | 35 | $1,283 |
| Solifenacin Succinate | 38 | $1,204 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 69 | $1,168 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 11 | $877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $558 | $234,677260 claims |
| Astellas Pharma US IncMyrbetriq | $274 | $196,058189 claims |
| PfizerPremarin | $290 | $6,51113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,955 physician assistant providers in Indiana.
Other physician assistant in Carmel
- Kristen GumpfCarmel$142K
- Linda ProkaiCarmel$10K
- Kayla JohnsonCarmel$8K
- Andrew NordIndianapolis$47K
- Qun Ming ZhangIndianapolis$28K
- Lauren HoweMunster$28K
- A FergusonFort Wayne$22K
- Jacquelyn BeemerFort Wayne$21K
- Lindsay YoderIndianapolis$21K
- Eryn GormanClinton$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.